Gentian Diagnostics ASA (OSL:GENT)

Market Cap	601.47M -20.4%
Revenue (ttm)	176.50M +16.1%
Net Income	13.26M -70.7%
EPS	0.86 -70.1%
Shares Out	15.42M
PE Ratio	45.37
Forward PE	14.89
Dividend	0.60 (1.54%)
Ex-Dividend Date	May 6, 2026

Volume	7,733
Average Volume	14,326
Open	38.60
Previous Close	38.10
Day's Range	38.60 - 39.70
52-Week Range	36.10 - 65.80
Beta	0.32
RSI	43.12
Earnings Date	Mar 20, 2026

About Gentian Diagnostics ASA

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidne...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 64
• Stock Exchange: Oslo Børs
• Ticker Symbol: GENT

Financial Performance

In 2025, Gentian Diagnostics ASA's revenue was 176.50 million, an increase of 16.07% compared to the previous year's 152.07 million. Earnings were 13.26 million, a decrease of -70.73%.